Table 5.

Cox regression survival analyses

	Hazard ratio	95% CI for HR	Total P-value
Univariate analysis
Base model
FIGO stage
III-IV vs I-II	5.98	3.11–9.89	< 0.001
Age (years)
> 60 vs ≤60	2.31	1.24–4.58	0.013
Grade
1 vs 2	2.59	1.16–4.86	0.062
Myometrial invasion
> 50% vs ≤50%	3.28	1.83–5.92	< 0.001
LVSI
yes vs no	2.63	1.24–4.76	0.009
Additions to modela
VEGF-A	1.02	0.25–3.64	0.74
Ang-2	1.29	1.09–1.59	< 0.001
Adiponectin	1.01	0.99–1.06	0.923
Insulin	1.00	0.98–1.02	0.914
C-peptide	1.02	0.97–1.06	0.689
CRP	1.37	1.03–1.61	< 0.001
IGF-1	1.01	0.96–1.05	0.893
BMI	0.84	0.45–1.41	0.472
Multivariate analysis
Base model
FIGO stage
III-IV vs I-II	3.57	1.79–6.94	< 0.001
Age (years)
> 60 vs ≤60	2.21	1.19–4.32	0.017
Grade
1 vs 2	1.52	1.18–2.96	0.683
Myometrial invasion
> 50% vs ≤50%	1.11	0.49–2.09	0.861
LVSI
yes vs no	1.16	0.53–2.36	0.734
Additions to modelb
Ang-2	1.31	1.02–1.69	0.006
CRP	1.22	1.01–1.43	0.015

^aThe base model consisted of traditional prognostic factors, and we separately entered the parameters in a second block

^bAdditions to the used model (all continuous, log-transformed, and separately entered)